Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass | MicrobiomeTrials
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2024-08-21Est. Completion: 2028-03
Enrollment target: 120 participants
Locations
Stanford University School of Medicine, Stanford, California, United States
University of Miami, Miami, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Duke University Medical Center, Durham, North Carolina, United States
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
Cleveland Clinic, Cleveland, Ohio, United States
The Ohio State University, Columbus, Ohio, United States
OU Health University of Oklahoma Medical Center, Oklahoma City, Oklahoma, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
University Hospital Innsbruck, Innsbruck, Austria
Vienna General Hospital AKH, Medical University of Vienna, Vienna, Austria
Royal Columbian Hospital, New Westminster, British Columbia, Canada
Kingston Health Sciences Centre, Kingston, Ontario, Canada
Toronto General Hospital, Toronto, Ontario, Canada
Montreal Heart Institute, Montreal, Quebec, Canada
Center of Cardiovascular and Transplant Surgery, Brno, Czechia
Other microbiome trials you might be interested in